Skip to content
Triangle logo TriangleGet started
← Study library

NCT02581462 · CITED IN SOURCE DOCUMENTS

FLOT vs. FLOT/Herceptin/Pertuzumab for Perioperative Therapy of HER-2 Expressing Gastric or GEJ Cancer

An NCI or FDA source cites this study. A citation does not establish that it applies to an individual diagnosis.

Phase
PHASE2, PHASE3
Status at capture
COMPLETED
Registry last update
2020-08-11

Previous studies provide a strong theoretical rationale for the conduct of a randomized study evaluating the efficacy and safety of Herceptin and pertuzumab in combination with FLOT in the perioperative treatment of resectable HER-2 positive adenocarcinoma of the stomach or GEJ.

Open the original ClinicalTrials.gov record → · Download preserved record

What did the study report?

Outcomes, safety and baseline populations are separate source sections. Quality-of-life measures appear under their original outcome titles.

No posted result sections were captured. Registered plans do not establish that a treatment works.

Who could take part
eligibility Criteria
Inclusion Criteria: 1. Histologically confirmed adenocarcinoma of the GEJ (type I-III) or the stomach (uT2, uT3, uT4, any N category, M0), or any T N+ M0 patient, with the following specifications: * Medical and technical operability * Centralized detection of either an adenocarcinoma with HER-2 3+ (IHC) or HER-2 2+ (IHC) with amplification proven by FISH, SISH or CISH 2. No preceding cytotoxic or targeted therapy 3. No prior partial or complete tumor resection 4. Exclusion of the infiltration of any adjacent organs or structures by CT or MRI 5. Exclusion of distant metastasis by CT or MRI of thorax and abdomen, and bone scan (if osseous lesions are suspected due to clinical signs) 6. Female and male patients ≥ 18 years. Patients in reproductive age must be willing to use adequate contraception during the study and for 7 months after the end of pertuzumab and Herceptin treatment (Appropriate contraception is defined as surgical sterilization (e.g., bilateral tubal ligation, vasectomy), hormonal contraception (implantable, patch, oral), and double-barrier methods (any double combination of: IUD, male or female condom with spermicidal gel, diaphragm, sponge, cervical cap)). Female patients with childbearing potential need to have a negative pregnancy test within 7 days before study start. 7. ECOG ≤ 2 8. Laparoscopic exclusion of peritoneal carcinomatosis, if suspected clinically 9. Adequate haematological, hepatic and renal function parameters: * Leukocytes ≥ 3.000/mm³, platelets ≥ 100.000/mm3 * Serum creatinine ≤ 1.5 x upper limit of normal, or GFR \> 40 ml/min * Bilirubin ≤ 1.5 x upper limit of normal, AST and ALT ≤ 3.5 x upper limit of normal, alkaline phosphatase ≤ 6 x upper limit of normal 10. LVEF value \> 55 %, as assessed by echocardiography 11. Patient able and willing to provide written informed consent and to comply with the study protocol and with the planned surgical procedures Exclusion Criteria: 1. Patients with involved retroperitoneal (e.g. para-aortal, paracaval or interaortocaval lymph nodes) or mesenterial lymph nodes (distant metastasis!) 2. Known hypersensitivity against Herceptin, pertuzumab, 5-FU, leucovorin, oxaliplatin, or docetaxel 3. Other known contraindications against Herceptin, pertuzumab, 5-FU, leucovorin, oxaliplatin, or docetaxel 4. Documented history of congestive heart failure of any NYHA, myocardial infarction within the past 6 months before the first dose of study treatment 5. Clinically significant valvular defect , history of poorly controlled arterial hypertension (systolic blood pressure \> 180 mmHG or diastolic blood pressure \> 100 mmHg) or uncontrollable high-risk cardiac arrhythmia (i.e tachycardia with a heart rate \> 100/min at rest), significant ventricular arrhythmia (ventricular tachycardia) or higher grade atrioventricular-block (second degree AV-block Type 2 (Mobitz2) or third degree AV-block) 6. Past or current history of other malignancies not curatively treated and without evidence of disease for more than 5 years, except for curatively treated basal cell carcinoma of the skin and in situ carcinoma of the cervix 7. Known brain metastases 8. Other severe internal disease or acute infection 9. Peripheral polyneuropathy ≥ NCI Grade II 10. Chronic inflammatory bowel disease 11. Clinically significant active GI bleeding 12. On-treatment participation in another clinical study in the period 30 days prior to inclusion and during the study 13. Subject pregnant or breast feeding, or planning to become pregnant within 6 months after the end of treatment. 14. Patients in a closed institution according to an authority or court decision (AMG § 40, Abs. 1 No. 4) 15. Any other concurrent antineoplastic treatment including irradiation
healthy Volunteers
false
maximum Age
99 Years
minimum Age
18 Years
sex
ALL
std Ages
  1. ADULT
  2. OLDER_ADULT
Treatment arms and interventions
arm Groups
  1. description
    Pre-operative therapy with FLOT followed by surgical resection followed by post-operative therapy with FLOT
    intervention Names
    1. Drug: FLOT alone
    label
    FLOT alone
    type
    EXPERIMENTAL
  2. description
    Pre-operative therapy with FLOT + Herceptin/Pertuzumab followed by surgical resection followed by post-operative therapy with FLOT + Herceptin/Pertuzumab
    intervention Names
    1. Biological: FLOT + Herceptin/Pertuzumab
    label
    FLOT + Herceptin/Pertuzumab
    type
    EXPERIMENTAL
interventions
  1. arm Group Labels
    1. FLOT alone
    description
    Pre-operative therapy: * Docetaxel 50 mg/m², d1, d15, d29, d43 * Oxaliplatin 85 mg/m², d1, d15, d29, d43 * Leucovorin 200 mg/m², d1, d15, d29, d43 (can be replaced by sodium folinate according to local guidelines) * 5-FU 2600 mg/m², d1, d15, d29, d43 Surgery is recommended to be scheduled 4 weeks after d43. Post-operative therapy (start 6 to 8 weeks after surgery): * Docetaxel 50 mg/m², d1, d15, d29, d43 * Oxaliplatin 85 mg/m², d1, d15, d29, d43 * Leucovorin 200 mg/m², d1, d15, d29, d43 (can be replaced by sodium folinate according to local guidelines) * 5-FU 2600 mg/m², d1, d15, d29, d43
    name
    FLOT alone
    type
    DRUG
  2. arm Group Labels
    1. FLOT + Herceptin/Pertuzumab
    description
    Pre-operative therapy: * Herceptin 8/6 mg/kg, d1, d22, d43 * Pertuzumab 840 mg, d1, d22, d43 * Docetaxel 50 mg/m², d1, d15, d29, d43 * Oxaliplatin 85 mg/m², d1, d15, d29, d43 * Leucovorin 200 mg/m², d1, d15, d29, d43 (can be replaced by sodium folinate according to local guidelines) * 5-FU 2600 mg/m², d1, d15, d29, d43 Surgery is recommended to be scheduled 4 weeks after d43. Post-operative therapy (start 6 to 8 weeks after surgery): * Herceptin 8/6 mg/kg, d1, d22, d43 * Pertuzumab 840 mg, d1, d22, d43 * Docetaxel 50 mg/m², d1, d15, d29, d43 * Oxaliplatin 85 mg/m², d1, d15, d29, d43 * Leucovorin 200 mg/m², d1, d15, d29, d43 (can be replaced by sodium folinate according to local guidelines) * 5-FU 2600 mg/m², d1, d15, d29, d43.
    name
    FLOT + Herceptin/Pertuzumab
    type
    BIOLOGICAL
Study design
allocation
RANDOMIZED
intervention Model
PARALLEL
masking Info
masking
NONE
primary Purpose
TREATMENT
Enrollment
count
81
type
ACTUAL
Registered outcome plans (not posted results)
primary Outcomes
  1. measure
    PhaseII: Rate of pathological complete response
    time Frame
    3 years
  2. measure
    Phase III: Median Progression Free Survival
    time Frame
    5 years
secondary Outcomes
  1. measure
    Phase II/III: R0 resection rate
    time Frame
    75 days
  2. measure
    Phase II: Median Progression Free Survival (PFS)
    time Frame
    3 years
  3. measure
    Phase II/III: Median Overall Survival
    time Frame
    3/5 years
  4. measure
    Phase II: PK Analysis
    time Frame
    3 years
  5. measure
    Phase II/III: Subgroup analyses: pathological response according to HER-2 status HER-2 IHC 3+ vs. other cases
    time Frame
    3/5 years
  6. measure
    Phase II/III: Subgroup analyses: PFS according to HER-2 status HER-2 IHC 3+ vs. other cases
    time Frame
    3/5 years
  7. measure
    Phase II/III: Subgroup analyses: OS according to HER-2 status HER-2 IHC 3+ vs. other cases
    time Frame
    3/5 years
  8. measure
    Phase III: Pathological Response Rates
    time Frame
    5 years
  9. measure
    Phase III: PFS rates
    time Frame
    3 and 5 years
  10. measure
    Phase III: OS rates
    time Frame
    3 and 5 years
  11. measure
    Phase III: Median OS
    time Frame
    5 years
Full study description
brief Summary
Previous studies provide a strong theoretical rationale for the conduct of a randomized study evaluating the efficacy and safety of Herceptin and pertuzumab in combination with FLOT in the perioperative treatment of resectable HER-2 positive adenocarcinoma of the stomach or GEJ.
detailed Description
This is a multicenter, randomized, controlled, open-label study including patients with locally advanced adenocarcinoma of the stomach and GEJ scheduled to receive perioperative chemotherapy. According to centrally assessed HER-2 status: Patients with HER-2 positive tumors will receive FLOT +/- Herceptin / pertuzumab. The scope of the phase II portion of the trial is to evaluate pathological response rates of either regimen assessed by a centralized pathology and define safety and tolerability. Patients with locally advanced esophagogastric adenocarcinoma (i.e. cT2 any N or any T N-positive) with exclusion of distant metastases will be included in this trial. Patients will be stratified by age (18-69 vs. ≥ 70), tumor site (GEJ vs. gastric) and clinical stage (T1/2 vs. 3/4 and N- vs. N+) and randomized 1:1 to receive either FLOT (Arm A) or FLOT/Herceptin/pertuzumab (Arm B). Arm A (control group) Patients randomized to Arm A will receive 4 pre-operative treatments of FLOT (Docetaxel 50 mg/m², iv over 2 h; Oxaliplatin 85 mg/m² in 500 ml G5%, iv over 2h; Leucovorin 200 mg/m² in 250 ml NaCl 0.9 %, iv over 1 h; 5-FU 2600 mg/m², iv over 24 h) on d1, d15, d29, d43 of the preoperative treatment phase. Surgery is recommended to occur 4 weeks after last FLOT (4 weeks after d43 = day 71). Patients will receive 4 additional post-operative treatments of FLOT on d1, d15, d29, and d43 of the post-operative treatment phase. Post-operative treatment should start 6 to 8 weeks, but at maximum 12 weeks after surgery. Arm B (Herceptin/pertuzumab group) Patients randomized to Arm B will receive the FLOT regimen identical to Arm A as described above in conjunction with three-weekly Herceptin at 8mg/kg initial dose (Day 1, loading dose) followed by subsequent doses of Herceptin at 6mg/kg on d22 and d43 and pertuzumab at 840mg on d1, d22, and d43. Surgery is recommended to occur 4 weeks after last FLOT/Herceptin/pertuzumab dose (4 weeks after d43 = day 71). Patients will receive 3 additional doses of Herceptin and pertuzumab on d1, d22, and d43 of the post-operative treatment phase, together with the postoperative chemotherapy. Moreover, patients will receive 11 additional doses of Herceptin and pertuzumab after the end of post-operative FLOT. In both of the arms, tumor assessments (CT or MRI) are performed before randomization and prior to surgery and then every 3 months thereafter until progression/relapse, death or end of follow-up. During treatment, clinical visits (blood cell counts, detection of toxicity) occur prior to every treatment dose. Safety of FLOT/Herceptin/pertuzumab will be monitored continuously by careful monitoring of all adverse events (AEs) and serious adverse events (SAEs) reported.
Source references
references
  1. citation
    Hofheinz RD, Merx K, Haag GM, Springfeld C, Ettrich T, Borchert K, Kretzschmar A, Teschendorf C, Siegler G, Ebert MP, Goekkurt E, Mahlberg R, Homann N, Pink D, Bechstein W, Reichardt P, Flach H, Gaiser T, Battmann A, Oduncu FS, Loose M, Sookthai D, Pauligk C, Goetze TO, Al-Batran SE. FLOT Versus FLOT/Trastuzumab/Pertuzumab Perioperative Therapy of Human Epidermal Growth Factor Receptor 2-Positive Resectable Esophagogastric Adenocarcinoma: A Randomized Phase II Trial of the AIO EGA Study Group. J Clin Oncol. 2022 Nov 10;40(32):3750-3761. doi: 10.1200/JCO.22.00380. Epub 2022 Jun 16.
    pmid
    35709415
    type
    DERIVED
Source notices and limitations
    Discovery and provenance
    1. release id
      ctgov-registry-7ad944f6deaf1f5cd6122126
      edge id
      nct-edge-db714baafde4bf2c4f6d
      requested nct id
      NCT02581462
      primary nct id
      NCT02581462
      source kind
      nci_explicit_reference_or_link
      source record id
      Source null
      source file sha256
      ae34307bb691d47c46a65f222a59b130903b0bb6f81f74d86efa8d978235c117
      payload sha256
      6f255eb9d7840dadf5e0e92af7ff935504f41d7c35f664ea1ff8a2514256d8bc
      payload
      clinical indication matching status
      not_inferred
      end exclusive
      true
      id
      nct-edge-db714baafde4bf2c4f6d
      link basis
      explicit_NCT_identifier_in_acquired_source
      nct id
      NCT02581462
      occurrences
      1. context exact
        erapy plus trastuzumab and pertuzumab): </p> <div class="pdq-content-list"><ol id="_566"><li>A multicenter phase II/III trial (<a href="/clinicaltrials/NCT02581462">NCT02581462</a>) included patients with human epidermal growth factor receptor 2 (HER2)-positive resectable gastric or gastroesophageal junction adenocarcinom
        end
        135237
        exact text
        NCT02581462
        start
        135226
      2. context exact
        astuzumab and pertuzumab): </p> <div class="pdq-content-list"><ol id="_566"><li>A multicenter phase II/III trial (<a href="/clinicaltrials/NCT02581462">NCT02581462</a>) included patients with human epidermal growth factor receptor 2 (HER2)-positive resectable gastric or gastroesophageal junction adenocarcinoma (clinical T
        end
        135250
        exact text
        NCT02581462
        start
        135239
      offset unit
      unicode_code_points
      source file
      /tmp/cancer-full-research/nci/raw/18487e92114483e1e7.html
      source file sha256
      ae34307bb691d47c46a65f222a59b130903b0bb6f81f74d86efa8d978235c117
      source json pointer
      Source null
      source kind
      nci_explicit_reference_or_link
      source record id
      Source null
      source retrieved at
      2026-09-09T23:21:40.423603+00:00
      source string basis
      UTF-8_text_with_universal_newline_translation
      source string sha256
      a637b94429a42b90c83abf50e8a31e75014f7c2723832c386417963ac519dbcf
      source title
      Esophageal Cancer Treatment (PDQ®)–Health Professional Version
      source update dates
      1. context
        Updated: March 21, 2025
        datetime
        2025-03-21T12:00:00Z
        display
        March 21, 2025

    Preserved source evidence · Not medical advice